Clinical Trials Logo

Clinical Trial Summary

The goal of this interventional study is to compare sensitivity of regular chest x-ray to ultra-low-dose computed tomography to find pulmonary relapse in follow-up of soft tissue sarcoma. The main question[s] it aims to answer are: - Is ultra-low-dose computed tomography more sensitive than regular chest x-ray to find pulmonary relapse? - Does ultra-low-dose computed tomography detect the most fast-growing pulmonary metastases earlier than regular chest x-ray? Participants will have seven ultra-low-dose computed tomography imagings in addition to simultaneous routine protocol of chest x-rays. Participants therefore work as their own controls.


Clinical Trial Description

After primary treatment with curative intent for soft tissue sarcoma, patients fulfilling the inclusion criteria and giving informed consent are enrolled. In study protocol patients have their regular chest x-ray once in two months plus ultra-low-dose computed tomography imaging is repeated seven times during the first two years of follow-up. After two years patients without detectable metastases continue in regular follow-up program. The aims of this prospective comparative study are to investigate whether ultra-low-dose computed tomography is more accurate than chest x-ray in soft tissue sarcoma and especially whether the most fast-growing pulmonary metastases could be detected earlier. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05813808
Study type Interventional
Source Helsinki University Central Hospital
Contact
Status Completed
Phase N/A
Start date June 1, 2017
Completion date January 15, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT06114004 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) Phase 2
Completed NCT01949506 - (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas N/A
Recruiting NCT04595994 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05235100 - Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma Phase 2
Completed NCT04991883 - Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
Recruiting NCT04122872 - GISAR German Interdisciplinary Sarcoma Registry
Recruiting NCT04910126 - Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma Phase 2
Recruiting NCT04219202 - Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Recruiting NCT05167994 - Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma Phase 2
Recruiting NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2
Recruiting NCT05813327 - Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04172805 - Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Phase 2
Active, not recruiting NCT04887298 - Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases Phase 1/Phase 2
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Recruiting NCT05894018 - Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT06263231 - A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) Phase 3
Completed NCT01985295 - Combined Modality Treatment of Sarcomas of the Extremities Phase 1